In the case of GBA and LRRK2, two of the most prevalent genetic forms of PD, sufficient numbers of people with PD carrying mutations in these genes exist such that multi-site clinical trials can be designed focused solely on enrolling mutation carriers. This evidence concerns the gene LRRK2 and Parkinson disease.